On January 10th, Lilly Pharmaceuticals announced that Encore&Co; Reg; Jiakanezumab Injection has officially been approved by the National Medical Products Administration for the preventive treatment of adult migraines. Enjiale; Reg; It is a humanized IgG4 monoclonal antibody that can bind to calcitonin gene related peptide (CGRP) and block the binding of CGRP to its receptor, thereby achieving the therapeutic goal of preventing migraine. It is the first approved drug in China for the treatment of migraines by Eli Lilly Pharmaceuticals.